New study validates the prognostic value of the HER2DX test in HER2-positive breast cancer
Researchers from the Clínic Barcelona Comprehensive Cancer Center—driven by Hospital Clínic Barcelona, IDIBAPS, and the University of Barcelona—toget1
Researchers from the Clínic Barcelona Comprehensive Cancer Center—driven by Hospital Clínic Barcelona, IDIBAPS, and the University of Barcelona—toget1
The Clínic Barcelona Comprehensive Cancer Center (4CB), driven by Hospital Clínic, IDIBAPS, and the University of Barcelona, strengthens its internat1
“I didn’t know what my present or my future would be like. I was very scared”, recalls Olga Federico of the time when she was diagnosed with breast1
The creation of the Clínic Barcelona Comprehensive Cancer Center represents a step forward in the integration of care, clinical research, translation1
Researchers from Hospital Clínic-IDIBAPS have led a study that has found a correlation between anti-tumour immunological activity and longevity in br1
Researchers from the Clínic-IDIBAPS, along with researchers from the Dana Farber Cancer Institute (DFCI) in Boston, have published a review on dual H1
Five researchers from the Clínic-IDBAPS were recognized with various grants worth a total of €122,000 at the Spanish Society of Medical Oncology (SEO1
Researchers from the Clínic-IDIBAPS have coordinated a study that analyses the efficacy of anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) combin1
This year, FERO will contribute €200,000, with which it will seek to provide structural and sustained support for the Molecular Diagnostics Programme1
These awards are organized by the Spanish Metastatic Breast Cancer Association to promote research in this area. The project presented by Dr. Aleix1